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Abstract
Opioids are commonly used as effective analgesics for the treatment of acute and chronic pain. However, considerable
individual differences have been widely observed in sensitivity to opioid analgesics. We focused on a G-protein-activated
inwardly rectifying potassium (GIRK) channel subunit, GIRK2, that is an important molecule in opioid transmission. In our
initial polymorphism search, a total of nine single-nucleotide polymorphisms (SNPs) were identified in the whole exon, 59-
flanking, and exon-intron boundary regions of the KCNJ6 gene encoding GIRK2. Among them, G-1250A and A1032G were
selected as representative SNPs for further association studies. In an association study of 129 subjects who underwent major
open abdominal surgery, the A/A genotype in the A1032G SNP and -1250G/1032A haplotype were significantly associated
with increased postoperative analgesic requirements compared with other genotypes and haplotypes. The total dose
(mean6SEM) of rescue analgesics converted to equivalent oral morphine doses was 20.4569.27 mg, 10.8462.24 mg, and
13.0762.39 mg for the A/A, A/G, and G/G genotypes in the A1032G SNP, respectively. Additionally, KCNJ6 gene expression
levels in the 1032A/A subjects were significantly decreased compared with the 1032A/G and 1032G/G subjects in a real-time
quantitative PCR analysis using human brain tissues, suggesting that the 1032A/A subjects required more analgesics
because of lower KCNJ6 gene expression levels and consequently insufficient analgesic effects. The results indicate that the
A1032G SNP and G-1250A/A1032G haplotype could serve as markers that predict increased analgesic requirements. Our
findings will provide valuable information for achieving satisfactory pain control and open new avenues for personalized
pain treatment.
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Introduction
Opioids are commonly used as effective analgesics for the
treatment of acute and chronic pain. However, sensitivity to opioid
analgesics is well known to vary widely among individual subjects
[1]. Individual differences can be attributed to both genetic and
environmental factors, although the relative influence of each of
these factors can be diverse [2]. Genetic variations in opioid-
related genes involved in opioid pharmacokinetics and pharma-
codynamics might lead to individual differences in phenotypes
related to pharmacological actions of opioid analgesics.
Numerous molecules are involved in the pharmacological effects
of opioids. Opioid ligands bind to opioid receptors, and the signal
is transmitted to a variety of effectors (e.g., adenylate cyclase,
calcium ion channels, and G-protein-activated inwardly rectifying
potassium [GIRK] channels), thereby resulting in analgesic effects
[3]. The genes encoding these molecules are candidates for
researching the relationships between genetic variations and
individual differences in phenotypes related to opioid actions.
Among opioid-related genes, GIRK channels are attractive
targets for the investigation of the relationship between genetic
variations and sensitivity to opioid analgesics because they play a
key role in opioid-induced analgesia [3]. Additionally, recent
quantitative trait locus analysis and computational mapping have
identified Kcnj9 (mouse Girk3) as a candidate gene affecting
variability in the analgesia induced by multiple drug classes [4].
GIRK channels are members of the inwardly rectifying potassium
channel family, and four subtypes (GIRK1-GIRK4) have been
identified in mammals [5]. GIRK channels are expressed in many
tissues, including the heart [6], spinal cord [7,8], and various
regions in the brain with different subunit compositions [9–11].
GIRK channel activation is triggered by activation of several Gi/o
protein-coupled receptors, including opioid receptors [12]. Several
studies using knockout mice have shown that opioid-induced
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7060GIRK channel activation co-expressed with opioid receptors leads
to inhibition of nociceptive transmission and thus opioid-induced
analgesia [6,7,13–15].
To date, however, few studies have examined the relationship
between genetic variations in GIRK channels and phenotypic
differences in humans, although several studies have identified
human GIRK channel gene polymorphisms [16–18]. Therefore,
the present study focused on GIRK channel gene polymorphisms,
particularly those of the KCNJ6 gene encoding GIRK2 because it
has been investigated more extensively than the other subtypes
with regard to its involvement in analgesia [6,7,13–15]. We sought
to reveal the relationship between genetic variations in the KCNJ6
gene and individual differences in opioid analgesic sensitivity.
Methods
Ethics Statement
The study protocol was approved by the Institutional Review
Boards at the Institute of Medical Science, The University of
Tokyo (Tokyo, Japan), Toho University Sakura Medical Center
(Sakura, Japan), and the Tokyo Institute of Psychiatry (Tokyo,
Japan). All subjects provided informed, written consent for the
genetics studies.
Subjects
Subjects for the resequencing of the KCNJ6 gene were recruited
from the Kanto area in Japan. A total of 48 unrelated healthy
subjects were used in the study so that polymorphisms with allele
frequency more than approximately 1% could be detected. The
oral mucosa of the participants was collected for gene analysis.
The subjects used in the association study were 129 patients
who underwent major open abdominal surgery, mostly gastrecto-
my for gastric cancer and colectomy for colorectal cancer, under
combined general and epidural anesthesia at Research Hospital,
Institute of Medical Science, The University of Tokyo, or at Toho
University Sakura Medical Center. Peripheral blood or oral
mucosa samples were collected from these subjects for gene
analysis.
To examine KCNJ6 gene expression levels, a total of 105 human
DNA samples extracted from human occipital cortex and 100
RNA samples extracted from human anterior cingulate cortex of
the same specimens were additionally obtained from the Stanley
Medical Research Institute (Bethesda, MD) as samples indepen-
dent of that in the association study (SMRI samples).
Clinical data
Postoperative pain was managed primarily with continuous
epidural analgesia with fentanyl or morphine. Fentanyl or
morphine was diluted with 0.25% bupivacaine in a total volume
of 100 ml and infused at a constant rate of 2 ml/h through a
catheter placed in the lower thoracic or upper lumbar epidural
space. Whenever the patient complained of significant postoper-
ative pain despite continuous epidural analgesic, appropriate doses
of opioids, including morphine, buprenorphine, pentazocine, and
pethidine, and/or nonsteroidal anti-inflammatory drugs
(NSAIDs), including diclofenac and flurbiprofen, were adminis-
tered as rescue analgesics at the discretion of surgeons. The clinical
data sampled included age, gender, body height, body weight,
postoperative diagnosis, type of operation, duration of operation,
and doses of rescue analgesics (opioids and/or NSAIDs)
administered during the first 24 h postoperative period, for which
analgesic therapy would be required in most patients. The study
subjects were also asked to rate their pain intensity at rest during
the first 24 h postoperative period using a 5-point verbal
numerical rating scale (NRS; 0=no pain, 1=mild pain,
2=moderate pain, 3=severe pain, 4=extremely severe pain).
To allow intersubject comparisons of rescue analgesic doses
required during the first 24 h postoperative period, doses of opioids
and NSAIDs administered as rescue analgesics during this period
were converted to the equivalent dose of oral morphine according
to a previous report [19]. The conversion factor used for the
different analgesics to derive equivalent doses of oral morphine
is presented in Table 1. The frequency of rescue analgesic
administration was determined as the frequency of use of rescue
analgesics during the first 24 h postoperative period. The total dose
of rescue analgesics administered was calculated as the sum of oral
morphine-equivalent doses of all opioidsand NSAIDs administered
to patients as rescue analgesics during the same period.
Resequencing KCNJ6 and SNP selection for the
association study
To comprehensively screen polymorphisms in the KCNJ6 gene,
resequencing was performed using an ABI PRISMH 3100 Genetic
Analyzer (Life Technologies Japan Ltd., Tokyo, Japan) for the
human KCNJ6 (GIRK2) gene regions (mapped to 21q22.13–q22.2)
and 59-flanking region based on the nucleotide sequences of the
GenBank database (accession number: NT_011512). The
screened regions contained all consensus sequences of exon
regions, exon-intron boundary regions (approximately 30 bp),
and putative promoter regions (approximately 1.8 kbp) for the
gene. The total length of the screened regions approximately
amounted to 4.5 kbp (Figure 1). All primers used for the screening
are shown in Table 2.
Single-nucleotide polymorphisms (SNPs) for the association
studies were selected based on several factors, including recently
advanced tagging strategies [20–22]. To identify relationships
between the SNPs identified in the polymorphism screening,
linkage disequilibrium (LD) analysis was performed using Haplo-
view v. 3.32 [23]. For estimation of LD strength between the SNPs,
the commonly used D9 and r
2 values were pairwise calculated using
the genotype dataset of each SNP. LD blocks were defined among
the SNPs showing ‘‘strong LD,’’ based on the default algorithm of
Gabriel et al. [24], in which the upper and lower 95% confidence
limits on D9 for strong LD were set at 0.98 and 0.7, respectively.
Tag SNPs in the LD block were consequently determined by the
software package Tagger, which is incorporated in Haploview and
has been detailed in a previous report [22].
Table 1. Estimated systemic dose equipotent to 90 mg oral
morphine (mg).
Analgesics Dose Reference
Morphine (oral) 90 [39]
Morphine (intravenous) 30 [39]
Morphine (epidural) 6 [39,40]
Pentazocine 90 [39,41]
Buprenophine 1 [39,41]
Petidine 360 [39,42]
Fentanyl 0.3 [39,43]
Diclofenac 300 [39,43–45]
Flurbiprofen 300 [39,43–47]
Indomethacin 300 [39,43–47]
doi:10.1371/journal.pone.0007060.t001
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Total genomic DNA was extracted from peripheral blood or
oral mucosa samples by standard procedures.
For genotyping KCNJ6 G-1250A, the polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method
and direct sequencing were adopted. To perform PCR-RFLP, the
restriction enzyme BsmI (Toyobo Co., Ltd., Tokyo, Japan) and two
primers of P5F and P6R were used (Table 2). First, PCR was
performed in a final volume of 10 ml containing 56GoTaq
TM
reaction buffer (7.5 mM magnesium), 0.16 mM dioxyribonucleo-
side triphosphate (dNTP), 0.4 mM of each primer, 0.5 U GoTaq
TM
DNA polymerase (Promega K.K. Japan, Tokyo, Japan), and 5–
50 ng extracted genomic DNA as the template. The PCR program
was the following: 95uC for 2 min, followed by 35 cycles of 95uC for
30 s, 60uC for 30 s, and 72uC for 1 min, with a final extension at
72uCfor8 min.TheamplifiedDNAfragmentsweredigestedbythe
restriction enzyme at 65uC in a total of 15 ml reaction solution
containing 106M buffer (100 mM Tris-HCl, pH 7.5, 100 mM
MgCl2, 500 mM NaCl, 10 mM dithiothreitol), 0.3 U BsmI, and
3.5 ml PCR product as the substrate. The digestion products were
analyzed by electrophoresis using 1–2% agarose gel and ethidium
bromide staining for visualization under ultraviolet illumination.
The appearanceof only the 601 bpDNAfragment correspondedto
the A/A genotype of the loaded sample. The appearance of both
the 233 bp and 370 bp fragments corresponded to the G/G
genotype, and the appearance of all three 601 bp, 233 bp, and
370 bp DNA fragments corresponded to the G/A genotype. The
failure rate of the RFLP genotyping assays was 1.667%.
For genotyping KCNJ6 A1032G, the PCR-RFLP method,
TaqMan allelic discrimination assay (Life Technologies Japan
Ltd.) and direct sequencing were adopted. To perform PCR-RFLP,
the restriction enzyme BspEI (New England Biolabs, Inc., Ipswich,
MA) was used. The forward primer P23F and the reverse primer
P24R were used (Table 2). First, PCR was performed in a final
volume of 10 mlc o n t a i n i n g5 6GoTaq
TM reaction buffer (7.5 mM
magnesium), 0.16 mM dNTP, 0.4 mMo fe a c hp r i m e r ,0 . 5U
GoTaq
TM DNA polymerase (Promega K.K. Japan, Tokyo, Japan),
and 5–50 ng extracted genomic DNA as the template. The PCR
program was the following: 95uC for 2 min, followed by 35–40
cycles of 95uC for 30 s, 50uC for 30 s, and 72uCf o r1m i n ,w i t ha
final extension at 72uC for 8 min. The amplified DNA fragments
were digested by the restriction enzyme at 37uC in a total of 10 ml
reaction solution containing 106NEBuffer 3 (500 mM Tris-HCl,
pH 7.9, 100 mM MgCl2, 1000 mM NaCl, 10 mM dithiothreitol),
0.5 U BspEI, and 5 ml PCR product as the substrate. The digestion
products were analyzed by electrophoresis using 1–2% agarose gel
and ethidium bromide staining for visualization under ultraviolet
illumination. A 65 bp digested DNA fragment is not easily
distinguishable; therefore, the appearance of 395 bp, 332 bp, and
both 395 bp and 332 bp DNA fragments corresponded to the A/A,
G/G, and A/G genotypes, respectively, of the loaded sample. The
failure rate of the RFLP genotyping assays was 3.571%. To perform
the TaqMan allelic discrimination assay with a LightCycler 480
(Roche Diagnostics K.K., Tokyo, Japan), TaqManH SNP Genotyp-
ing Assays (Life Technologies Japan Ltd.) containing sequence-
specific forward and reverse primers to amplify the polymorphic
sequence and two probes labeled with VICH and FAM
TM dye to
detect both alleles of the KCNJ6 A1032G (Assay ID:
C_15868122_10) were used. Real-time PCR was performed in a
final volume of 10 mlc o n t a i n i n g2 6LightCyclerH 480 Probes Master
(Roche Diagnostics K.K.), 406TaqManH Gene Expression Assays,
5 ng genomic DNA as the template, and up to 10 mlH 2Oe q u i p p e d
with 26LightCyclerH 480 Probes Master. The thermal condition
wasthefollowing:95uCfor10 min,followedby45cyclesof95uCfo r
10 s and 60uC for 60 s, with a final cooling at 50uC for 30 s.
Afterward, endpoint fluorescence was measured for each sample
well, and the A/A, A/G, and G/G genotypes were determined
based on the presence or absence of each type of fluorescence.
For samples that were difficult to genotype for KCNJ6 G-1250A
and KCNJ6 A1032G using the PCR-RFLP method, direct
sequencing was adopted to determine the sequence with both
forward and reverse primers enclosing the SNP sites.
Real-time quantitative PCR (qPCR)
The SMRI RNA samples were treated with DNase I using
RNase-Free DNase Set (QIAGEN K.K., Tokyo, Japan) at room
temperature (20–25uC) for 10 min, and then clean-up was
performed using RNeasyH MinEluteH Cleanup Kit (QIAGEN).
Figure1.The positionofthe SNPsidentified inthe polymorphismscreeningfor the KCNJ6 gene. The filledbox and striped box representthe
codingregionanduntranslatedregion,respectively. Thehorizontalarrowsindicate thescreenedregions.Thenumbersabove theboxes andin the exonic
SNPs are relative positions from the transcription start site (+1) in the KCNJ6 mRNA, and the number ‘‘75167’’ in the IVS1C75167T SNP is the relative
position from the intron 1 start site in the genomic DNA. The underlined SNPs show absolute linkage disequilibrium between one another (D’=1,r
2=1).
doi:10.1371/journal.pone.0007060.g001
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the SuperScriptIII First-Strand synthesis system for qRT-PCR
(Life Technologies Japan Ltd.) with 100 ng purified total RNA
according to the manufacturer’s protocol.
To perform real-time qPCR utilizing a LightCycler 480 (Roche
Diagnostics K.K.), TaqManH Gene Expression Assays (Life
Technologies Japan Ltd.) were used as a probe/primer set
specified for the KCNJ6 gene (Assay ID: Hs01040524_m1) and a
probe/primer set for the ACTB gene, a house-keeping gene,
encoding b-actin (Assay ID: Hs99999903_m1). PCR was per-
formed in a final volume of 20 ml containing 26LightCyclerH 480
Probes Master, 1 ml TaqManH Gene Expression Assay, 1 ml
cDNA as the template, and up to 20 mlH 2O equipped with
26LightCyclerH 480 Probes Master. The PCR program was the
following: 95uC for 10 min, 45 cycles of 95uC for 10 s and 60uC
for 30 s, followed by 95uC for 10 s, 50uC for 30 s, 50–70uC
(continuously) at a rate 0.06uC/s, with a final cooling at 50uC for
30 s. The expression level of the KCNJ6 gene was normalized to
that of the ACTB gene for each sample, and relative KCNJ6
mRNA expression levels between all samples were compared by
setting the lowest expression level among all SMRI samples as 1.
Experiments were performed in duplicate (separate experiments)
for each sample, and averaged values were calculated for
normalized expression levels.
Predictions of mRNA secondary structure
To discuss in depth mRNA sequence and function, the
secondary structure for KCNJ6 mRNA was predicted using Mfold
web server (v. 3.2) with default settings [25]. The KCNJ6 mRNA
position 982–1082 was used to predict the local structure of the
mRNA based on the nucleotide sequences of the GenBank
database (accession number: NM_002240.2).
Statistical analysis
The x
2 test or Fisher exact test was performed for all genotype
frequency data using FreeJSTAT 8.2 for Windows (free software by
Table 2. Primers used in the analyses.
Gene Region Sequence Forward/Reverse Primer No.
KCNJ6 59-flanking TCCCAGTTGCAGTGGACAGGAC Forward P1F
AAATCCCCGGTTAGGAGAAAAGTG Reverse P2R
CCAGTTATTGAAAGGGCCATTATA Forward P3F
CTAAGTAAGTTATTCCCGGAGAAA Reverse P4R
CAGGCATTGTGGAGCACGTATTAC Forward P5F
CACCCCCTCTTTTTCTTATGGTCA Reverse P6R
AATGGGATCCATCTCATTCAACAC Forward P7F
AGAAGGCTTACGGAAACCTCTTAT Reverse P8R
Exon 1 CGGCGGGGTGGGCGTCTC Forward P9F
CCCCCGTGCGAGTTTCAGTCG Reverse P10R
TCGCCCCCGCCCCTTCCT Forward P11F
TCCCTCGCCTTTCGGCTGACTTG Reverse P12R
Exon 2 TTTTGAAAACTGGTCGTGCGTCAC Forward P13F
TTCTGTCTGAAATTTCTGAACG Reverse P14R
Exon 3 AAGTCAACTAGAGGCCTATCCAGA Forward P15F
CTAAGGTCCCCTACCCGGAACATC Reverse P16R
CTGGTGGGCAGGATGGTGAA Forward P17F
TCTCTGCCCTCTTCTTGGGTTGAG Reverse P18R
TTGATCGCATACATACGGGGAGAC Forward P19F
GTCATGAAGCAAGGGGATGTTGTC Reverse P20R
TGGCTACCGGGTCATCACAGATAA Forward P21F
GGCTTCTTGGTGGATATACTTCAG Reverse P22R
TTCTCAATAGAGACAGAAACCACCATTGGT- Forward P23F
TATGGCTACCGGGTCATCACAGATAAATGT
GACACCAGAAACAGACGGTCATC Reverse P24R
GGATGAACTCCCCCTCCGAGGTCT Reverse P25R
Exon 4 ACCTACTAAGTGTGGCATCGTATG Forward P26F
AACACATGCAGGTAAGTAACTGAA Reverse P27R
CCCTAGCTGGGCAAACCCTTCTC Forward P28F
TTCCCCCAGACCTATGGCTTGTTG Reverse P29R
TGTGGCAAACCTGGAGAATGAATC Forward P30F
GATCCGTGTGGGAACAGTGAGGTA Reverse P31R
Forward/Reverse, sense/antisense strand sequences of the gene, respectively; Primer No., the ID number of the primer described in the paper.
doi:10.1371/journal.pone.0007060.t002
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jp/soft/win95/business/se030917.html) or Simple Interactive Sta-
tistical Analysis (free software by Quantitative Skills, The Nether-
lands; current version is available at http://www.quantitativeskills.
com/sisa/) to investigatethedeviation of thedistributionsfromthose
in the theoretical Hardy-Weinberg equilibrium. Analysis of
covariance (ANCOVA) was performed to examine the contribution
of the SNPs to the subjective pain ratings reported by patients,
frequency of 24 h analgesic requirements, and analgesic require-
ments during the 24 h postoperative period. Bonferroni multiple
comparisons were used as post hoc tests. Correction of multiple testing
was notperformed forthe results ofthe G-1250A andA1032G SNPs
in this explorative study. The age, height, and weight of the subjects
were incorporated as covariables for the ANCOVA because these
threefactorswerefoundtobesignificantcovariablesinapreliminary
analysisandmay affectanalgesicefficacyofopioidsand/or NSAIDs.
Pearson’s correlation coefficient (r) was calculated to examine the
correlation between variables. Student’s t-test was performed to
compare KCNJ6 expression levels between the A1032G genotype
subgroups. For these three analyses, SPSS 12.0J for Windows (SPSS
Japan,Inc.,Tokyo,Japan) wasused. Poweranalyses wereperformed
usingG*PowerVersion3.0.5[26].gPLINKv.2.049,PLINKv.1.01
(http://pngu.mgh.harvard.edu/purcell/plink/) [27], and Haplo-
view v. 4.0 [23] were used for haplotype-specific tests, incorporating
gender, age, height, and weight of the subjects as covariables, with
the false discovery rate set at 0.05 for correction of multiple testing,
based ona previousreport[28].In allstatisticaltests,thecriterionfor
significance was set at P,0.05.
Results
In the first polymorphism search in the whole exon, 59-flanking,
and exon-intron boundary regions of the KCNJ6 gene, a total of
nine SNPs were identified in the 59-flanking region, intron 1, exon
3, and exon 4. Figure 1 illustrates the relative positions of the SNPs
identified in the KCNJ6 gene. The characteristics of the SNPs are
provided in Table 3, where the minor allele frequencies of the
SNPs are also shown. The allele frequencies of the SNPs observed
in this study were comparable (less than 0.1 difference) to those
annotated in the National Center for Biotechnology Information
(NCBI) database (Table 3). SNPs for a further association study
were selected, considering the LD structure, minor allele
frequencies of the SNPs, and the expected impact on gene
function. The results of the D’ and r
2 calculations for the KCNJ6
gene are provided in Table 4. Absolute LD (D’=1, r
2=1) was
observed between SNPs G-1250A, T-244C, and C-227T (Table 4),
Table 3. The characteristics of the identified SNPs in the KCNJ6 gene.
Position SNP name rs ID Sample size Reported allele Major allele Minor allele Minor allele frequency
59-flanking A-1361G – 48 A A G 0.010 (N.A.)
G-1250A rs6517442 48 G A G 0.385 (0.422)
T-244C rs7275707 46 T C T 0.391 (0.422)
C-227T rs7276069 46 C T C 0.391 (0.422)
A-68G rs11702683 45 A G A 0.089 (0.102)
Intron 1 IVS1C75167T rs2836016 48 C T C 0.188 (0.273)
Exon 3 A1032G rs2070995 48 A G A 0.344 (0.432)
Exon 4 C1569T rs702859 48 C T C 0.062 (0.100)
C1843G rs56345212 48 C C G 0.052 (N.A.)
rs ID, reference SNP ID in the NCBI dbSNP database; Sample size, the number of samples used for genotyping each SNP; Reported allele, the allele appearing in the
GenBank reference sequence. The numbers in parentheses represent the minor allele frequencies for the Japanese population described in the NCBI dbSNP database.
N.A., not available.
doi:10.1371/journal.pone.0007060.t003
Table 4. Pairwise D’ and r
2 values between the identified SNPs in the KCNJ6 gene.
D’
SNP name A-1361G G-1250A T-244C C-227T A-68G IVS1C75167T A1032G C1569T C1843G
A-1361G – 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
G-1250A 0.017 – 1.000 1.000 1.000 0.136 0.037 0.518 0.159
T-244C 0.017 1.000 – 1.000 1.000 0.114 0.020 0.505 0.104
r
2 C-227T 0.017 1.000 1.000 – 1.000 0.114 0.020 0.505 0.104
A-68G 0.000 0.153 0.153 0.153 – 0.191 0.398 0.152 0.093
IVS1C75167T 0.002 0.007 0.005 0.005 0.014 – 0.078 1.000 0.044
A1032G 0.020 0.000 0.000 0.000 0.034 0.003 – 0.603 0.401
C1569T 0.001 0.029 0.028 0.028 0.000 0.015 0.046 – 0.091
C1843G 0.192 0.002 0.001 0.001 0.004 0.000 0.017 0.007 –
The numbers above and below the hyphens show the results of the pairwise calculations of D’ and r
2 between the two SNPs, respectively. The values representing
D’=1.000 are underlined. The pairs of values representing D’=1.000 and r
2=1.000 are italicized and bold.
doi:10.1371/journal.pone.0007060.t004
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tagging SNP in this LD block structure. The minor allele
frequencies for these three SNPs were relatively high (Table 3),
and G-1250A was selected for the association study. Among the
remaining six SNPs, IVS1C75467T and A1032G are relatively
common, with minor allele frequencies greater than 0.1, and could
be candidates for an association study. Because IVS1C75467T is
in the intron region and thus is less likely to affect the mRNA
product or protein levels, it was not selected as a candidate SNP.
Therefore, G-1250A and A1032G were selected from the nine
KCNJ6 SNPs for the association study.
The genotype distributions for the two SNPs that were selected
were not significantly different from the theoretical Hardy-
Weinberg equilibrium values in independent tests of the 48
healthy subjects used in the resequencing procedure or 129 patient
subjects used in the association analyses (data not shown). The
clinical data of the 129 subjects who were included in the
association study are provided in Table 5. Rescue analgesics were
required in 59 patients. Doses of rescue analgesics administered to
patients are shown in Table 5. More detailed clinical data stratified
by each genotype (KCNJ6 G-1250A and A1032G) are presented as
Supporting Information in Table S1.
Two-way ANCOVA was performed to examine the effects of
SNPs and gender on the frequency of rescue analgesic adminis-
tration, the total dose of rescue analgesics administered, and NRS
pain scores, incorporating the age, height, and weight of the
subjects as covariables. Statistical power analyses for the
ANCOVA revealed that the expected power (1 minus type II
error probability) was 71% for the Cohen’s conventional
‘‘medium’’ effect size 0.25 [29] when the sample size was 129
and type I error probability was set at 0.05. Significant associations
were not observed between KCNJ6 G-1250A and the frequency of
rescue analgesic administration or total dose of rescue analgesics
administered (frequency of rescue analgesic administration:
F2,117=1.145, P=0.322; total dose of rescue analgesics adminis-
tered: F2,117=1.233, P=0.295). A significant main effect of
KCNJ6 A1032G on the frequency of rescue analgesic administra-
tion was observed (F2,120=5.336, P=0.006). Post hoc analysis
revealed significant differences between the A/A and A/G
genotypes (P=0.005) and between the A/A and G/G genotypes
(P=0.010), indicating that the carriers of the A/A genotype in the
A1032G SNP required rescue analgesics more often compared
with carriers of the A/G and G/G genotypes (Figure 2A). The
effect of KCNJ6 A1032G on the total dose of rescue analgesics
administered was not significant (F2,120=1.332, P=0.268).
However, a significant main effect of the KCNJ6 A1032G SNP
on the total dose of rescue analgesics administered was observed in
the female subjects (F2,49=3.428, P=0.040), and differences were
Table 5. The clinical data of the subjects included in the study.
N Minimum Maximum Mean SD
KCNJ6 G-1250A
G/G (male/female) 19 (11/8)
G/A (male/female) 72 (42/30)
A/A (male/female) 35 (19/16)
KCNJ6 A1032G
A/A (male/female) 11 (5/6)
A/G (male/female) 62 (37/25)
G/G (male/female) 56 (32/24)
Gender
male 74
female 55
Age 129 28 80 63.57 9.92
Height (cm) 129 133 175 158.21 8.34
Weight (kg) 129 35 80 56.24 10.42
NRS pain score 105 0 4 1.54 1.29
male/female 62/43 0/0 4/4 1.48/1.63 1.21/1.40
Frequency of analgesic administration 129 0 6 0.72 1.01
male/female 74/55 0/0 3/6 0.70/0.75 0.90/1.14
Total dose of rescue analgesics (mg) 129 0 105 12.63 19.16
male/female 74/55 0/0 72/105 13.38/11.62 19.05/19.44
Dose of each rescue analgesic (mg) 129 (0) (105) (12.63) (19.16)
Epidural morphine (mg) 2 0.5 (7.5) 2 (30) 1.25 (18.75) 1.06 (15.91)
Pentazocine (mg) 24 15 (15) 75 (75) 26.25 (26.25) 17.83 (17.83)
Buprenophine (mg) 15 0.2 (18) 0.8 (72) 0.47 (42.00) 0.16 (14.70)
Petidine (mg) 1 35 (8.75) 35 (8.75) 35.00 (8.75) –
Diclofenac (mg) 14 25 (7.5) 100 (30) 37.50 (11.25) 23.51 (7.054)
Flurbiprofen (mg) 8 50 (15) 100 (30) 62.50 (18.75) 23.15 (6.944)
Values in parentheses for ‘‘Dose of each rescue analgesic (mg)’’ indicate data for dose of each rescue analgesic converted to the equivalent oral morphine dose.
doi:10.1371/journal.pone.0007060.t005
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marginally significant between the A/A and G/G genotypes
(P=0.061) in the post hoc analysis (Figure 2B), whereas such
differences were not observed in male subjects (F2,68=0.032,
P=0.969). Neither the main effect of gender nor the SNP6gender
interaction was significant (data not shown). Significant associa-
tions were not observed between the two SNPs and NRS pain
scores (G-1250A: F2,94=1.455, P=0.239; A1032G: F2,96=0.115,
P=0.892), although significant positive correlations were found
between NRS pain scores and frequency of rescue analgesic
administration (r=0.281, P=0.004) and between NRS pain scores
and total dose of rescue analgesics administered (r=0.266,
P=0.006), indicating that the patients who received analgesics
more frequently felt more pain, possibly attributable to insufficient
analgesic effects.
To examine in more detail the association between KCNJ6
SNPs and rescue analgesic requirements, a haplotype-based test
was performed. As shown in Table 6A, a significant association
was found between the 21250G/1032A haplotype and the
increased frequency of rescue analgesic administration in all
patient subjects (R
2=0.120, adjusted P=0.015). Although no
significant associations were observed between each of the KCNJ6
haplotypes and total dose of rescue analgesics administered in all
patient subjects and male subjects (R
2=0.080, P=0.328;
R
2=0.028, P=0.765, respectively), the 21250G/1032A haplo-
type was significantly associated with total dose of rescue
analgesics administered in female subjects (R
2=0.277, adjusted
P=0.038; Table 6B). Associations between each of the G-1250A/
A1032G haplotypes and NRS pain scores were not significant
(data not shown).
To estimate the impact of the KCNJ6 A1032G polymorphism
on gene expression level, the relative KCNJ6 mRNA expression
level was compared between the genotype subgroups of the SMRI
samples in the real-time qPCR. The relative expression level
(mean6SEM) was 1.5960.17, 2.0760.08, and 1.9960.06 for the
A/A, A/G, and G/G genotypes in the A1032G SNP, respectively
(Figure 3), demonstrating that the expression level was 0.76–0.80
fold lower in the A/A genotype than in the A/G and G/G
genotype. The difference was significant between the A/A
genotype and combined A/G and G/G genotypes (t98=2.265,
P=0.026).
Figure 2. Association analysis between requirements for rescue
analgesics and SNPs. The results for the frequency of analgesic
administration (A) and the total dose of analgesics administered per
weight (B) during the 24 h postoperative period are shown for the
KCNJ6 A1032G SNP. The white, striped, and filled boxes indicate results
for male, female, and all subjects, respectively. (A) *: significantly more
frequent administration for the A/A genotype compared with the A/G
and G/G genotypes in all subjects, {: significantly more frequent
administration for the A/A genotype compared with the A/G and G/G
genotypes in female subjects. (B) {: significantly greater dose of
analgesic administration for the A/A genotype compared with the A/G
genotype in female subjects.
doi:10.1371/journal.pone.0007060.g002
Table 6. Association of KCNJ6 haplotypes with postoperative analgesia.
A
Haplotype Frequency Beta R
2 F PP
a
21250G/1032A 0.1517 0.6313 0.1197 8.8080 0.0036
{ 0.0145
*
21250A/1032A 0.1736 20.0216 0.0546 0.0101 0.9203 0.9203
21250G/1032G 0.2848 20.0754 0.0563 0.2211 0.6391 0.8521
21250A/1032G 0.3898 20.2179 0.0711 2.1290 0.1472 0.2944
B
Haplotype Frequency Beta R
2 F PP
a
21250G/1032A 0.1394 0.3139 0.2771 7.3160 0.0094
{ 0.0377
*
21250A/1032A 0.2032 20.0160 0.1673 0.0192 0.8903 1.0000
21250G/1032G 0.2865 20.0273 0.1687 0.0995 0.7538 1.0000
21250A/1032G 0.3709 20.1054 0.1951 1.6770 0.2015 0.8903
Association of the haplotype composed of the G-1250A/A1032G SNPs with (A) the frequency of analgesic administration in all patient subjects or (B) the total dose of
analgesics administered during the 24 h postoperative period in female patient subjects. Frequency, haplotype frequency; Beta, regression coefficient; R
2, coefficient of
determination; F, F statistic; P, crude P value; P
a, adjusted P value for multiple testing.
{P,0.05,
*P
a,0.05.
doi:10.1371/journal.pone.0007060.t006
KCNJ6 SNPs and Analgesia
PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e7060Discussion
The present study comprehensively examined KCNJ6 genetic
variations in humans and explored the associations between these
variations and outcomes in clinical pain management. To our
knowledge, the present study is the first to explore SNPs of the
KCNJ6 gene with regard to associations between these SNPs and
postoperative analgesic requirements in humans. We found that
carriers of the A/A genotype in the A1032G SNP or 21250G/
1032A haplotype required rescue analgesics more often and
tended to require higher doses of rescue analgesics, especially in
female subjects, compared with carriers of other genotypes or
haplotypes, respectively, after major open abdominal surgery
(Figure 2A and B, Table 6). Although we did not show all of the
results of multiple testing for the G-1250A and A1032G SNPs with
the Bonferroni correction because this study was explorative, the P
value for the main effect of KCNJ6 A1032G on the frequency of
rescue analgesic administration was 0.012 after the Bonferroni
correction. This suggests that this SNP is likely to affect sensitivity
to analgesics, although we must concede that this significance
might possibly occur by chance alone. Patients who experienced
more severe pain, evaluated by NRS pain scores, required higher-
dose and more frequent rescue analgesics, although significant
associations were not observed between the A1032G SNP or
21250G/1032A haplotype and NRS pain scores. Moreover,
KCNJ6 gene expression levels in the 1032A/A subjects was
significantly decreased compared with 1032A/G and 1032G/G
subjects in the real-time qPCR analysis using human brain tissues,
suggesting that the 1032A/A subjects required more analgesics
because of lower KCNJ6 gene expression levels and consequently
insufficient analgesic effects. Altogether, these results suggest that
subjects carrying the A/A genotype in the A1032G SNP or
21250G/1032A haplotype, especially in females, had lower
sensitivity to analgesics and, therefore, required more rescue
analgesics than subjects carrying other genotypes or haplotypes to
achieve a similar degree of pain relief.
For our ANCOVA analyses, the desirable sample size was
calculated as 158 for the effect size 0.25 to achieve 80% power.
This might suggest that a sample size of 129 subjects in our study
was somewhat insufficient to reliably detect moderate differences
between the SNP genotypes, and a far greater sample may be
required to detect smaller differences. Considering this caveat and
relatively small effect size observed in the haplotype analysis (e.g.,
R
2 for haplotype effect on the frequency of analgesic administra-
tion was 0.120), future studies with larger sample sizes may reveal
additional associations between polymorphisms and opioid
sensitivity.
In the initial polymorphism screening for KCNJ6, a total of nine
SNPs were identified in the whole exon, 59-flanking, and exon-
intron boundary regions (Figure 1). Polymorphisms that might
cause significant functional changes, such as nonsynonymous or
insertion/deletion polymorphisms, were not found in the poly-
morphism screening of the human KCNJ6 gene in the present
study, possibly attributable to the importance and high conserva-
tion of mammalian GIRK channels. A possible explanation
derives from studies in weaver mice, in which only a single missense
mutation in the pore region of the mouse Kcnj6 gene causes various
aberrant changes in cerebellar granule cells [30], membrane
permeability [31], loss of K
+ selectivity [32,33], significantly lower
analgesia compared with wildtype mice [3], and lack of activating
effects of ethanol [34]. The Kcnj6 gene orthologs might be under
purifying selection over many generations of the species, including
human and mouse, because of the profound functional constraints
attributable to the importance of these orthologs in these
organisms.
The A/A genotype in the A1032G SNP was significantly
associated with increased postoperative analgesic requirements in
our study. The G allele appears to be dominant in mediating the
transmission of intensified opioid signaling compared with the A
allele. However, this particular SNP is synonymous and causes no
amino acid change; therefore, the protein structure encoded by
this gene may not be altered by this SNP. Nevertheless, local
structural difference in the 1023–1059 position was observed
between the sequences, including 1032A and 1032G, in our
prediction of the KCNJ6 mRNA secondary structure (Figure S1).
Whereas the 1032A mRNA formed an interior loop, a hairpin
loop, and a 6 bp helix, the 1032G mRNA formed a bulge loop as
well as an interior loop, a hairpin loop, and a 7 bp helix in the
local structure. Although the role of this difference in gene
function remains to be determined, the SNP may actually
influence mRNA expression level. Indeed, recent studies measur-
ing allelic expression imbalances [35] have demonstrated that even
a synonymous SNP could affect mRNA and protein levels [36],
possibly by altering mRNA stability and protein synthesis [37].
Similar mRNA and protein levels, but altered conformations, were
found for synonymous polymorphisms [38].
To further infer the precise mechanism underlying the increased
requirements for rescue analgesics in the A/A subjects in the
A1032G SNP, we compared the relative KCNJ6 mRNA
expression level between the genotype subgroups of the SMRI
samples in the real-time qPCR. A significant difference in
expression level was observed between the A/A genotype and
the combined A/G and G/G genotypes, consistent with the results
of the association study, in which only the subjects with the A/A
genotype in this SNP demonstrated significantly higher require-
ments for rescue analgesics than the other genotypes. The 1032A/
A subjects required more analgesics, probably because of lower
KCNJ6 gene expression levels and consequently insufficient
analgesic effects.
We do not have any evidence to explain how the 21250G/
1032A haplotype contributes to increased requirements for rescue
analgesics compared with other haplotypes. One might infer that
the G-1250A SNP in the putative regulatory region could be
related to some moderate functional alteration, and the 21250G
and 1032A alleles could be risk factors for decreased sensitivity to
analgesics. Both alleles might combine synergistically to cause
profound decreases in sensitivity to analgesics. Future functional
studies focusing on both the G-1250A and A1032G SNPs are
required to investigate this hypothesis.
Figure 3. Relative KCNJ6 mRNA expression level between each
genotype subgroup of the SMRI samples. *: significantly lower
expression level between the A/A genotype and combined A/G and G/
G genotypes in all subjects.
doi:10.1371/journal.pone.0007060.g003
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and 21250G/1032A haplotype were significantly associated with
increased analgesic requirements after major open abdominal
surgery. Furthermore, KCNJ6 gene expression levels in the
1032A/A subjects was significantly decreased compared with the
1032A/G and 1032G/G subjects. Although the association might
be restricted to the Japanese population, and the mechanism by
which individual sensitivity to postoperative analgesics is altered by
the G-1250A and A1032G SNPs remains to be fully elucidated,
the outcome indicates that the A1032G SNP and G-1250A/
A1032G haplotype could serve as markers that predict increased
analgesic requirements. Our findings will provide valuable
information to better modulate individual analgesic dosages
required to achieve satisfactory pain control and open new
avenues for personalized pain treatment.
Supporting Information
Table S1 The clinical data of the subjects stratified by genotype
Found at: doi:10.1371/journal.pone.0007060.s001 (0.12 MB
DOC)
Figure S1 Predicted secondary structure for the KCNJ6 mRNA
based on the nucleotide sequences of the GenBank database
(accession number: NM_002240.2). The sequences for KCNJ6
mRNA position 1012–1072 are presented for the 1032A (A) and
1032G (B) mRNA. The numbers next to the sequences indicate
relative positions from position 982.
Found at: doi:10.1371/journal.pone.0007060.s002 (0.99 MB TIF)
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